Hepatic angiomyolipoma

Changed by Henry Knipe, 1 Dec 2021

Updates to Article Attributes

Body was changed:

Hepatic angiomyolipomaangiomyolipomas (hepatic AML(AML) is anare uncommon benign hamartomatous hepatic mass lesionlesions, containing blood vessel (angioid), smooth muscle (myoid) and mature fat (lipoid) components. There is an association with tuberous sclerosis, although this is less strong than for renal AMLs.

Epidemiology

Associations

There is a reported correlation between hepatic angiomyolipoma and tuberous sclerosis (TS), although the association is not as strong atas it is with renal angiomyolipoma (AML). Up to 20% of renal AMLs are associated with tuberous sclerosis, compared to only 6% of hepatic AMLs 5. Nonetheless, the liver is the second most frequent site of angiomyolipoma after the kidney. 

Clinical presentation

Most reported cases of angiomyolipoma are detected incidentally.

However, initial presentation as acute abdominal pain related to intratumoral haemorrhage and intraperitoneal haemorrhage has been reported 8.

Pathology

Pathologically, an AML is anAMLs are unencapsulated lesionlesions with vascular, smooth muscle and mature fat components. Angiomyolipoma fat content can vary from less than 10% to more than 95%. Fat component is made up of mature yellow fat cells. At the microscopic examination, epithelioid smooth muscle cellcells and proliferating blood vessels are visible.

It may be classified histologically according to the amount of fat content into several subtypes 1:

  • mixed
  • lipomatous (>70% fat)
  • myomatous (<10% fat)
  • angiomatous

Immunohistochemical staining of the tumour cells reveals HMB-45 positivity.  Among hepatic tumours, HMB-45 reactivity is found exclusively in the smooth muscle cells of AMLs 7

Radiographic features

Angiomyolipomas may be single or multiple, round or lobulated fat-containing mass lesions, seen more commonly in the right hepatic lobe 3

The characteristic findings on any modality are the presence of both fat and prominent vascularity in the same lesion. If the fatty component predominates, it resembles lipomas but most of the time, a mixture of usual solid soft tissue intermingled with fatty components will be seen. Conversely, in cases of less fatty content and excess vascular part, the lesion seems like hypervascular hepatic mass lesions.

The drainage vein of AML is the hepatic vein, and identifying a perfusing vein communicating with the hepatic vein from the tumour centre can aid in differentiating AML from fat-containing hepatocellular carcinoma (HCC) 2,4.

Ultrasound

It may be seen as hetero or homogeneous echogenic (due to fat content) mass lesion. In the case of less fat content and excess vascular component, angiomyolipoma can be seen as a heterogeneous hypoechoic mass lesion. Could be indistinguishable from a hemangioma 1.

CT

On non-enhanced CT, angiomyolipoma presents as well defined solid heterogeneous mass containing markedly hypodense area. Due to the presence of the vascular component, marked enhancement in the arterial phase is evident. Drainage is via the hepatic veins, and this is the main differentiating point from fat-containing HCC that drains mainly in the portal vein.

  • NECT
    • well-defined mass with heterogeneous attenuation values due to the presence of fat and soft tissue densities
    • maybe predominantly low-density mass
  • arterial phase: significant enhancement in the arterial phase
  • portal phase: becomes hypoattenuatedhypoattenuating
MRI

On MRI the lesion shows hyperintensity like as fatty tissue on both T1 and T2, which decreases with fat suppression. To detect the small volume of fat content in cases of lipid-poor AML, chemical shift imaging (i.e. in-phase/out-of-phase) is useful.

Signal characteristics
  • T1
    • fatty components show hyperintensity on T1WI
    • loss of signal on fat suppressed-suppressed sequences
    • in cases of poor lipid-content in phase/out of phase will show loss of signal at out of phase
  • T2: fatty components show hyperintensity on T2WI
  • T1 C+ (Gd): enhancement of vascular component in arterial phase

Treatment and prognosis

Observation is the method of choice for asymptomatic cases. However, cases with severe abdominal pain or intraperitoneal bleeding not responding to conservative treatment can be treated successfully with embolization and/or surgical resection.

Differential diagnosis

General imaging differential considerations include:

  • hepatocellular carcinoma (HCC) with a fatty component
    • typically the fatty content is minimal and is in a scattered pattern
    • AFP is elevated and HMB-45 in cell staining is negative
  • focal fatty infiltration
    • poorly defined borders without pressure effect on adjacent vessels
  • haemangioma
    • may be indistinguishable on ultrasound
  • hepatic lipoma 
    • very uncommon
    • should contain no soft tissue component and never shows enhancement after contrast administration
  • metastasis from liposarcoma/teratoma
    • extremely uncommon
  • -<p><strong>Hepatic angiomyolipoma</strong> <strong>(hepatic AML)</strong> is an uncommon benign <a title="Hamartoma" href="/articles/hamartoma">hamartomatous</a> hepatic mass lesion, containing blood vessel (angioid), smooth muscle (myoid) and mature fat (lipoid) components. There is an association with <a title="Tuberous sclerosis" href="/articles/tuberous-sclerosis">tuberous sclerosis</a>, although this is less strong than for <a title="Renal AML" href="/articles/renal-angiomyolipoma">renal AMLs</a>.</p><h4>Epidemiology</h4><h5>Associations</h5><p>There is a reported correlation between hepatic angiomyolipoma and <a href="/articles/tuberous-sclerosis">tuberous sclerosis (TS)</a>, although the association is not as strong at it is with <a href="/articles/renal-angiomyolipoma">renal angiomyolipoma (AML)</a>. Up to 20% of renal AMLs are associated with tuberous sclerosis, compared to only 6% of hepatic AMLs <sup>5</sup>. Nonetheless, the liver is the second most frequent site of angiomyolipoma after kidney. </p><h4>Clinical presentation</h4><p>Most reported cases of angiomyolipoma are detected incidentally.</p><p>However, initial presentation as acute abdominal pain related to intratumoral haemorrhage and intraperitoneal haemorrhage has been reported<sup> 8</sup>.</p><h4>Pathology</h4><p>Pathologically, an AML is an unencapsulated lesion with vascular, smooth muscle and mature fat components. Angiomyolipoma fat content can vary from less than 10% to more than 95%. Fat component is made up of mature yellow fat cells. At the microscopic examination, epithelioid smooth muscle cell and proliferating blood vessels are visible.</p><p>It may be classified histologically according to the amount of fat content into several subtypes<sup> 1</sup>:</p><ul>
  • +<p><strong>Hepatic angiomyolipomas</strong> <strong>(AML)</strong> are uncommon benign <a href="/articles/hamartoma">hamartomatous</a> hepatic mass lesions, containing blood vessel (angioid), smooth muscle (myoid) and mature fat (lipoid) components. There is an association with <a href="/articles/tuberous-sclerosis">tuberous sclerosis</a>, although this is less strong than for <a href="/articles/renal-angiomyolipoma">renal AMLs</a>.</p><h4>Epidemiology</h4><h5>Associations</h5><p>There is a reported correlation between hepatic angiomyolipoma and <a href="/articles/tuberous-sclerosis">tuberous sclerosis (TS)</a>, although the association is not as strong as it is with <a href="/articles/renal-angiomyolipoma">renal angiomyolipoma (AML)</a>. Up to 20% of renal AMLs are associated with tuberous sclerosis, compared to only 6% of hepatic AMLs <sup>5</sup>. Nonetheless, the liver is the second most frequent site of angiomyolipoma after the kidney. </p><h4>Clinical presentation</h4><p>Most reported cases of angiomyolipoma are detected incidentally.</p><p>However, initial presentation as acute abdominal pain related to intratumoral haemorrhage and intraperitoneal haemorrhage has been reported<sup> 8</sup>.</p><h4>Pathology</h4><p>Pathologically, AMLs are unencapsulated lesions with vascular, smooth muscle and mature fat components. Angiomyolipoma fat content can vary from less than 10% to more than 95%. Fat component is made up of mature yellow fat cells. At the microscopic examination, epithelioid smooth muscle cells and proliferating blood vessels are visible.</p><p>It may be classified histologically according to the amount of fat content into several subtypes<sup> 1</sup>:</p><ul>
  • -<li>portal phase: becomes hypoattenuated</li>
  • +<li>portal phase: becomes hypoattenuating</li>
  • -<li>loss of signal on fat suppressed sequences</li>
  • +<li>loss of signal on fat-suppressed sequences</li>
  • -<a title="Hepatocellular carcinoma (HCC)" href="/articles/hepatocellular-carcinoma">hepatocellular carcinoma (HCC)</a> with a fatty component<ul>
  • +<a href="/articles/hepatocellular-carcinoma">hepatocellular carcinoma (HCC)</a> with a fatty component<ul>
  • -<a title="Serum AFP elevation" href="/articles/alpha-fetoprotein-1">AFP is elevated</a> and <a title="HMB-45" href="/articles/hmb-45">HMB-45</a> in cell staining is negative</li>
  • +<a href="/articles/alpha-fetoprotein-1">AFP is elevated</a> and <a href="/articles/hmb-45">HMB-45</a> in cell staining is negative</li>

References changed:

  • 1. Prasad S, Wang H, Rosas H et al. Fat-Containing Lesions of the Liver: Radiologic-Pathologic Correlation. Radiographics. 2005;25(2):321-31. <a href="https://doi.org/10.1148/rg.252045083">doi:10.1148/rg.252045083</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/15798052">Pubmed</a>
  • 2. John Robert Haaga. CT and MRI of the Whole Body. (2009) ISBN: 9780323053754 - <a href="http://books.google.com/books?vid=ISBN9780323053754">Google Books</a>
  • 3. Damaskos C, Garmpis N, Garmpi A et al. Angiomyolipoma of the Liver: A Rare Benign Tumor Treated with a Laparoscopic Approach for the First Time. In Vivo. 2017;31(6):1169-73. <a href="https://doi.org/10.21873/invivo.11185">doi:10.21873/invivo.11185</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/29102941">Pubmed</a>
  • 4. Zheng R & Kudo M. Hepatic Angiomyolipoma: Identification of an Efferent Vessel to Be Hepatic Vein by Contrast-Enhanced Harmonic Ultrasound. Br J Radiol. 2005;78(934):956-60. <a href="https://doi.org/10.1259/bjr/27365821">doi:10.1259/bjr/27365821</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/16177023">Pubmed</a>
  • 5. Cha I, Cartwright D, Guis M, Miller T, Ferrell L. Angiomyolipoma of the Liver in Fine-Needle Aspiration Biopsies: Its Distinction from Hepatocellular Carcinoma. Cancer. 1999;87(1):25-30. - <a href="https://www.ncbi.nlm.nih.gov/pubmed/10096356">Pubmed</a>
  • 6. Fricke B, Donnelly L, Casper K, Bissler J. Frequency and Imaging Appearance of Hepatic Angiomyolipomas in Pediatric and Adult Patients with Tuberous Sclerosis. AJR Am J Roentgenol. 2004;182(4):1027-30. <a href="https://doi.org/10.2214/ajr.182.4.1821027">doi:10.2214/ajr.182.4.1821027</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/15039181">Pubmed</a>
  • 7. Nonomura A, Mizukami Y, Takayanagi N et al. Immunohistochemical Study of Hepatic Angiomyolipoma. Pathol Int. 1996;46(1):24-32. <a href="https://doi.org/10.1111/j.1440-1827.1996.tb03529.x">doi:10.1111/j.1440-1827.1996.tb03529.x</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/10846546">Pubmed</a>
  • 8. Kim S, Kang T, Lim K, Joh H, Kang J, Sinn D. A Case of Ruptured Hepatic Angiomyolipoma in a Young Male. Clin Mol Hepatol. 2017;23(2):179-83. <a href="https://doi.org/10.3350/cmh.2016.0027">doi:10.3350/cmh.2016.0027</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28449573">Pubmed</a>
  • 1. Prasad SR, Wang H, Rosas H et-al. Fat-containing lesions of the liver: radiologic-pathologic correlation. Radiographics. 25 (2): 321-31. <a href="http://dx.doi.org/10.1148/rg.252045083">doi:10.1148/rg.252045083</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/15798052">Pubmed citation</a><div class="ref_v2"></div>
  • 2. Haaga JR, Boll D. CT and MRI of the whole body. Mosby. (2009) ISBN:0323053750. <a href="http://books.google.com/books?vid=ISBN0323053750">Read it at Google Books</a> - <a href="http://www.amazon.com/gp/product/0323053750">Find it at Amazon</a><span class="ref_v3"></span>
  • 3. CHRISTOS DAMASKOS, NIKOLAOS GARMPIS, ANNA GARMPI, AFRODITI NONNI, STRATIGOULA SAKELLARIOU, GEORGIOS-ANTONIOS MARGONIS, ELEFTHERIOS SPARTALIS, DIMITRIOS SCHIZAS, NIKOLAOS ANDREATOS, ELENI MAGKOUTI, ALEXANDROS GRIVAS, KONSTANTINOS KONTZOGLOU, MATTHEW J. WEISS, EFSTATHIOS A. ANTONIOU. Angiomyolipoma of the Liver: A Rare Benign Tumor Treated with a Laparoscopic Approach for the First Time. (2017) In Vivo. 31 (6): 1169. <a href="https://doi.org/10.21873/invivo.11185">doi:10.21873/invivo.11185</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/29102941">Pubmed</a> <span class="ref_v4"></span>
  • 4. Zheng RQ, Kudo M. Hepatic angiomyolipoma: identification of an efferent vessel to be hepatic vein by contrast-enhanced harmonic ultrasound. Br J Radiol. 2005;78 (934): 956-60. <a href="http://dx.doi.org/10.1259/bjr/27365821">doi:10.1259/bjr/27365821</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/16177023">Pubmed citation</a><div class="ref_v2"></div>
  • 5. Cha I, Cartwright D, Guis M et-al. Angiomyolipoma of the liver in fine-needle aspiration biopsies: its distinction from hepatocellular carcinoma. Cancer. 1999;87 (1): 25-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10096356">Pubmed citation</a><span class="ref_v3"></span>
  • 6. Fricke BL, Donnelly LF, Casper KA et-al. Frequency and imaging appearance of hepatic angiomyolipomas in pediatric and adult patients with tuberous sclerosis. AJR Am J Roentgenol. 2004;182 (4): 1027-30. <a href="http://dx.doi.org/10.2214/ajr.182.4.1821027">doi:10.2214/ajr.182.4.1821027</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/15039181">Pubmed citation</a><span class="ref_v3"></span>
  • 7. Nonomura A, Mizukami Y, Takayanagi N et-al. Immunohistochemical study of hepatic angiomyolipoma. Pathol. Int. 2000;46 (1): 24-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10846546">Pubmed citation</a><span class="ref_v3"></span>
  • 8. Kim SH, Kang TW, Lim K, Joh HS, Kang J, Sinn DH. A case of ruptured hepatic angiomyolipoma in a young male. (2017) Clinical and molecular hepatology. 23 (2): 179-183. <a href="https://doi.org/10.3350/cmh.2016.0027">doi:10.3350/cmh.2016.0027</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28449573">Pubmed</a> <span class="ref_v4"></span>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.